Company Overview and News

22
KLCI narrows loss, but remains in the red as Genting, CIMB weigh

2018-06-14 theedgemarkets
KUALA LUMPUR (June 14): The FBM KLCI narrowed its losses at market close today, but remained in the red in line with its regional peers, dragged by losses at Genting-related stocks and CIMB Group Holdings Bhd.
7251 MLYNF 5197 BATS 4162 GMALY 0133 1023 4715 PNAGF GEBHF HRGHY MLYBY SPMXF GMALF 5681 SNHHF 6432 5168 6033 CIMDF 5139 1155 PNADF SPMXY 0900 BSMAF 1818

7
Tread water ahead of U.S.-N.Korea summit, cenbank meetings

2018-06-11 theedgemarkets
(June 11): Southeast Asian stock markets trod water on Monday, ahead of a U.S.-North Korea summit that could lay the groundwork for ending a nuclear stand-off between the old foes, while investors also started to focus on key central bank meetings later this week.
GMALY 1155 MLYBY 4715 GMALF MLYNF

16
South-east Asia stocks tread water ahead of US-N. Korea summit, central bank meetings

2018-06-11 malaymail
SINGAPORE, June 11 — South-east Asian stock markets trod water today ahead of a US-North Korea summit that could lay the groundwork for ending a nuclear stand-off between the old foes, while investors also started to focus on key central bank meetings later this week.
GMALY 1155 JGSMY SMIVY SVTMF MLYBY 4715 GMALF JGS MLYNF SM JGSHF

29
Trading value of shares on Bursa surges to record high

2018-05-31 thestar.com.my
KUALA LUMPUR: Bursa Malaysia recorded the highest ever in trading value on Thursday at more than RM9bil as the FBM KLCI staged a steady rebound as the government unveiled more solid measures to strengthen the economy. At 5pm, the KLCI was up 21.34 points or 1.24% to 1,740.62. However, it managed to only recoup more than just one-third of the losses after falling more 56 points the previous day in a broad selloff.
PBLOF GMALF 4065 4197 5681 1295 6033 GMALY PNADF 4715 SMEBF 8869 5819 BSMAF PNAGF GEBHF 1818

12
Foreign investors sell off RM2.48bil of Malaysia shares; heaviest selldown since August 2013

2018-05-21 thestar.com.my
KUALA LUMPUR: Foreign funds reacted to the unprecedented outcome of Malaysia’s General Election (GE14) by dumping RM2.48bil of local equities last week.
GMALY 5225 4715 GMALF 5681 Q0F IHHHF GEBHF

16
Local funds shore up volatile market

2018-05-19 thestar.com.my
REVIEW: Bursa Malaysia in the post-election week reflected investor sentiment over the polling results with a show of confidence by local institutions keeping the market in good stead.
GMALY 3204 5226 PBLOF 4715 GMALF BATS 4162 1295 BSMAF 7078 1818

16
KLCI closes down 18pts as Maxis, CIMB and Maybank weigh

2018-05-02 thestar.com.my
KUALA LUMPUR: Blue chips closed on a weak note on Wednesday ahead of the 14th General Election on May 9 as investors decided to stay on the sidelines. At 5pm, the FBM KLCI was down 18.34 points or 0.98% to 1,852.03. Turnover was 2.10 billion shares valued at RM2.43bil. There were 311 gainers, 551 losers and 381 counters unchanged. Hong Kong stocks fell as investors braced for trade talks between US and Chinese officials, and awaited the US Federal Reserve's upcoming policy statement, Reuters reported.
GMALY PNADF PBLOF 4715 GMALF 5819 1295 PNAGF GEBHF 6033

9
Bursa Malaysia remains higher at mid-morning

2018-04-16 themalaymailonline
The Edit: Watch Han Solo and Chewie in this new ‘Solo: A Star Wars Story’ clip
GMALY 4715 GMALF BSMAF 1818

7
Genting plans to bid for Japan gaming licence

2018-04-09 thestar.com.my
PETALING JAYA: Genting Bhd is optimistic that the Japan Integrated Resort Execution Bill will be tabled in this year’s Diet session, paving the way for the group to formally bid for its Japan gaming licence.
GMALY G13 4715 GMALF 2291 GIGNF GEBHF GIGNY

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 37251V109